SEARCH

SEARCH BY CITATION

References

  • 1
    Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes. Diabetologia 2003; 46: 319.
  • 2
    Danaei G, Finucane MM, Lu Y et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet 2011; 378: 3140.
  • 3
    American Diabetes Association. Standards of Medical Care in Diabetes—2013. Diabetes Care 2013; 36(Suppl 1): S1166.
  • 4
    Committee CDACPGE. Clinical Practice Guidelines: pharmacologic management of Type 2 diabetes. Can J Diabetes 2013; 37(Suppl 1): s618.
  • 5
    Chinese Diabetes Society. China guideline for type 2 diabetes (2010 edition). Chin J Diabetes 2012; 20: S136.
  • 6
    UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33. Lancet 1998; 352: 83753.
  • 7
    UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34. Lancet 1998; 352: 85465.
  • 8
    Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999; 281: 200512.
  • 9
    Bell DSH. Management of type 2 diabetes with thiazolidinediones. Link between β-cell preservation and durability of response. The Endocrinologist 2004; 14: 2939.
  • 10
    Ovalle F, Bell DS. Clinical evidence of thiazolidinedione-induced improvement of pancreatic beta-cell function in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2002; 4: 569.
  • 11
    Kramer CK, Zinman B, Retnakaran R. Short-term intensive insulin therapy in type 2 diabetes mellitus: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 2013; 1: 2834.
  • 12
    Bunck MC, Diamant M, Corner A et al. One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. Diabetes Care 2009; 32: 7628.
  • 13
    Bunck MC, Corner A, Eliasson B et al. Effects of exenatide on measures of beta-cell function after 3 years in metformin-treated patients with type 2 diabetes. Diabetes Care 2011; 34: 20417.
  • 14
    Preumont V, Hermans MP, Brichard S, Buysschaert M. Six-month exenatide improves HOMA hyperbolic product in type 2 diabetic patients mostly by enhancing beta-cell function rather than insulin sensitivity. Diabetes Metab 2010; 36: 2938.
  • 15
    Wajchenberg BL. β-cell failure in diabetes and preservation by clinical treatment. Endocr Rev 2007; 28: 187218.
  • 16
    Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 4129.
  • 17
    Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 1999; 22: 146270.
  • 18
    DeFronzo RA, Banerji MA, Bray GA et al. Determinants of glucose tolerance in impaired glucose tolerance at baseline in the Actos Now for Prevention of Diabetes (ACT NOW) study. Diabetologia 2010; 53: 43545.
  • 19
    Utzschneider KM, Prigeon RL, Faulenbach MV et al. Oral disposition index predicts the development of future diabetes above and beyond fasting and 2-h glucose levels. Diabetes Care 2009; 32: 33541.
  • 20
    Zinman B, Schmidt WE, Moses A, Lund N, Gough S. Achieving a clinically relevant composite outcome of an HbA1c of <7% without weight gain or hypoglycaemia in type 2 diabetes: a meta-analysis of the liraglutide clinical trial programme. Diabetes Obes Metab 2012; 14: 7782.
  • 21
    Buse JB, Rosenstock J, Sesti G et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009; 374: 3947.
  • 22
    Meloni AR, Deyoung MB, Han J, Best JH, Grimm M. Treatment of patients with type 2 diabetes with exenatide once weekly versus oral glucose-lowering medications or insulin glargine: achievement of glycemic and cardiovascular goals. Cardiovasc Diabetol 2013; 12: 48.
  • 23
    Russell-Jones D, Cuddihy RM, Hanefeld M et al. Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study. Diabetes Care 2012; 35: 2528.
  • 24
    Herman WH, Dungan KM, Wolffenbuttel BH et al. Racial and ethnic differences in mean plasma glucose, hemoglobin A1c, and 1,5-anhydroglucitol in over 2000 patients with type 2 diabetes. J Clin Endocrinol Metab 2009; 94: 168994.
  • 25
    Bergenstal RM, Wysham C, Macconell L et al. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet 2010; 376: 4319.
  • 26
    Diamant M, Van Gaal L, Stranks S et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet 2010; 375: 223443.
  • 27
    Best JH, Hoogwerf BJ, Herman WH et al. Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database. Diabetes Care 2011; 34: 905.
  • 28
    Ji L, Onishi Y, Ahn CW et al. Efficacy and safety of exenatide once-weekly vs exenatide twice-daily in Asian patients with type 2 diabetes mellitus. J Diabetes Investig 2013; 4: 5361.
  • 29
    Yuan GH, Song WL, Huang YY, Guo XH, Gao Y. Efficacy and tolerability of exenatide monotherapy in obese patients with newly diagnosed type 2 diabetes: a randomized, 26 weeks metformin-controlled, parallel-group study. Chin Med J (Engl) 2012; 125: 267781.
  • 30
    Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35: 136479.
  • 31
    Xu W, Li J, Zeng L et al. Comparison of 24-week Treatment with Exenatide, Insulin and Pioglitazone in Newly Diagnosed and Drug-naïve T2DM. Diabetes 2012; 61(Suppl 1): A4.
  • 32
    Xu W, Bi Y, Sun Z et al. Comparison of glycemic control and beta-cell function in newly diagnosed type 2 diabetes patients treated with exenatide, insulin or pioglitazone: a multicentre, randomized, parallel-group trial (CONFIDENCE). Diabetes 2014; 63(Suppl 1): A86.